Celldex Therapeutics, Inc. has elected to prepay its term loans under its Loan and Security Agreement, dated as of December 30, 2010, by and among Celldex Therapeutics, Inc., Celldex Research Corporation, MidCap Financial, LLC, and General Electric Capital Corporation, as amended. pursuant to the terms of the Loan Agreement. Those term loans would have otherwise matured in December 2014. By prepaying the term loan in May 2013, the company will save approximately $0.5 million in interest expense, which would have been payable over the remaining term of the loan. On May 17, 2013, the company repaid in full its term loan under the MidCap Loan Agreement, repaying the remaining principal amount of approximately $8.8 million in addition to $0.7 million in interest, prepayment and final payment fees. As a result, the Loan Agreement was terminated. The company's obligations under the Loan Agreement had been secured by a first priority security interest in substantially all of its assets, other than its intellectual property. In connection with the termination of the Loan Agreement, those security interests are being released.

Celldex Therapeutics, Inc. Presents at Credit Suisse 2013 Antibody Day, May-10-2013 11:00 AM. Venue: New York, New York, United States. Speakers: Tibor Keller, Chief Scientific Officer and Senior Vice President.

Celldex Therapeutics, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, the company reported net loss of $17.3 million or $0.23 per basic and diluted share compared to a net loss of $13.5 million or $0.27 per basic and diluted share for the first quarter of 2012. The net loss represents an increased loss of approximately $3.8 million when compared to the net loss for the same period in 2012 and is primarily due to higher research and development (R&D) and general and administrative (G&A) expenses in 2013 related to the rindopepimut program. Revenues were consistent with revenues recorded in the first quarter of 2012. Operating loss was $17.40 million compared to $13.3 million reported a year ago. Total revenue was $2.41 million compared to $2.43 million reported a year ago.